Static magnetic field attenuates mortality rate of mice by increasing the production of IL-1 receptor antagonist

International Journal of Radiation Biology

Volumn 85, Issue 7, 2009, Pages 633-640

  Lin, Shu Li ^a   Chang, Wei Jen ^b   Lin, Yung Sheng ^c   Ou, Keng Liang ^b   Lin, Che Tong ^b   Lin, Chih Ping ^b   Huang, Haw Ming ^b  

^a CATHAY GENERAL HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c INSTRUMENT TECHNOLOGY RESEARCH CENTER   (Taiwan)

Author keywords

Disseminated intravascular coagulation; Lipopolysaccharide; Proinflammatory cytokine; Static magnetic field

Indexed keywords

INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISSEMINATED INTRAVASCULAR CLOTTING; IMMUNOMODULATION; MAGNETIC FIELD; MAGNETOTHERAPY; MALE; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE COUNT;

ANIMALS; DISSEMINATED INTRAVASCULAR COAGULATION; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; LIPOPOLYSACCHARIDES; MAGNETICS; MALE; MICE; MICE, INBRED BALB C; PLATELET COUNT;

ANIMALIA; MUS;

EID: 67651177574     PISSN: 09553002     EISSN: 13623095     Source Type: Journal    
DOI: 10.1080/09553000902993908     Document Type: Article

References (33)

1. Aldinucci C, Garcia JB, Oalmi M, Sgaragli G, Benocci A, Meini A, Pessina F, Rossi C, Bonechi C, Pessina GP. 2003. The effect of strong static magnetic field on lymphocytes. Bioelectromagnetics 24:109-117.
2. Asakura H, Takahashi Y, Kubo A, Ontachi T, Hayashi T, Omote M, Arahata M, Kadohira Y, Maekawa M, Yamazaki M, Morishita E, Takami A, Yoshida T, Miyamoto K, Nakao S. 2006. Immunoglobulin preparations attenuate organ dysfunction and hemostatic abnormality by suppressing the production of cytokines in lipopolysaccharide-induced disseminated intravascular coagulation in rats. Critical Care Medicine 34:2421-2425.
3. Ashdown H, Poole S, Boksa P, Luheshi GN. 2007. Interleukin-1 receptor antagonist as a modulator of gender differences in the febrile response to lipopolysaccharide in rats. The American Journal of Physiology - Regulatory, Integrative and Comparative Physiology 292:R1667-1674.
4. Bakhshi S, Arya LS. 2003. Etiopathophysiology of disseminated intravascular coagulation. Journal of the Association of Physicians of India 51:796-800.
5. Cummins D,SegalH, Hunt BJ,AwadR,MaddoxA.2001.Chronic disseminated intravascular coagulation after surgery for abdominal aortic aneurysm: Clinical and haemostatic response to dalteparin. British Journal of Haematology 113:658-660.
6. Dempfle CE. 2004. Coagulopathy of sepsis. Thrombosis and Haemostasis 91:213-224.
7. Dinarello CA. 1998. Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. International Reviews of Immunology 16:457-499.
8. Ergonul O, Tuncbilek S, Baykam N, Celikbas A, Dokuzoguz1 B. 2006. Evaluation of serum levels of interleukin (IL)- 6, IL-10, and tumor necrosis factor-A in patients with Crimean-Congo hemorrhagic fever. The Journal of Infectious Diseases 193:941-944.
9. Feinstein DI. 1982. Diagnosis and management of disseminated intravascular coagulation: The role of heparin therapy. Blood 60:284-287.
10. Fourrier F, Chopin C, Goudemand J, Hendryscx S, Caron C, Rime A, Marey A, Lestavel P. 1992. Septic shock, multiple
11. organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 101:816-823.
12. Goldbach-Mansky R, Dailey NJ, Canna SW, Gelabert A, Jones J, Rubin BI, et al. 2006. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1β inhibition. The New England Journal of Medicine 355:581-592.
13. Gullestad L, Aass H, Fjeld JG, Wikeby L, Andreassen AK, Ihlen H, Simonsen S, Kjekshus J, Nitter-Hauge S, Ueland T, Lien E, Frøland SS, Aukrust P. 2001. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation 103:220-225.
14. Hardaway RM. 2000. A review of septic shock. The American Surgeon 66:22-29.
15. Kakafika A, Papadopoulos V, Mimidis K, Mikhailidis DP. 2007. Coagulation, platelets, and acute pancreatitis. Pancreas 34: 15-20.
16. Kishimoto C, Shioji K, Kinoshita M, Iwase T, Tamaki S, Fujii M, Murashige A, Maruhashi H, Takeda S, Nonogi H, Hashimoto T. 2003. Treatment of acute inflammatory cardiomyopathy with intravenous immunoglobulin ameliorates left ventricular function associated with suppression of inflammatory cytokines and decreased oxidative stress. International Journal of Cardiology 91:173-178.
17. Lin CT, Lee SY, Chen CY, Chen CA, Lin CP, Huang HM. 2008. Long-term continuous exposure to static magnetic field reduces lipopolysaccharide-induced cytotoxicity of fibroblasts. International Journal of Radiation Biology 84:219-226.
18. Lynn WA. 1998. Anti-endotoxin therapeutic options for the treatment of sepsis. Journal of Antimicrobial Chemotherapy 41:A71-80.
19. Nahra R, Dellinger RP. 2008. Targeting the lipopolysaccharides: Still a matter of debate? Current Opinion in Anaesthesiology 21:98-104.
20. Norman KE, Cotter MJ, Stewart JB, Abbitt KB, Ali M, Wagner BE, Wallace WA, Forlow SB, Hellewell PG. 2003. Combined anticoagulant and antiselectin treatments prevent lethal intravascular coagulation. Blood 101:921-928.
21. Remick DG. 2007. Pathophysiology of sepsis. The American Journal of Pathology 170:1435-1444.
22. Rodel F, Keilholz L, Herrmann M, Sauer R, Hildebrandt G. 2007. Radiobiological mechanisms in inflammatory diseases of low-dose radiation therapy. International Journal of Radiation Biology 6:357-366.
23. Rothenburger M, Soeparwata R, Deng MC, Berendes E, Schmid C, Tjan TDT, Wilhelm MJ, Erren M, Böcker D, Scheld HH. 2001. The impact of anti-endotoxin core antibodies on endotoxin and cytokine release and ventilation time after cardiac surgery. Journal of the American College of Cardiology 38:124-130.
24. Salerno S, Lo Casto A, Caccamo N, D'Anna C, De Maria M, Lagalla R, Scola L, Cardinale AE. 1999. Static magnetic fields generated by a 0.5 T MRI unit affects in vitro expression of activation markers and interleukin release in human peripheral blood mononuclear cells (PBMC). International Journal of Radiation Biology 75:457-463.
25. Sato H, Konishi Y, Tanaka H, Takahashi O, Tanaka T. 2004. Annexin V inhibits lipopolysaccharide-induced procoagulant activity on human monocytes. Thrombosis Research 114:45-49.
26. Saunders R. 2005. Static magnetic fields: Animal studies. Progress in Biophysics and Molecular Biology 87:225-239.
27. Short MA. 2004. Linking the sepsis triad of inflammation, coagulation, and suppressed fibrinolysis toinfants. Advances in Neonatal Care 4:258-273.
28. Slofstra SH, Cate HT, Spek CA. 2006. Low dose endotoxin priming is accountable for coagulation abnormalities and organ damage observed in the Schwartzman reaction. A comparison between a single-dose endotoxemia model and a double-hit endotoxin-induced Shwartzman reaction. Thrombosis Journal 4:13-19.
29. Tilg H, Dinarello CA, Mier JW. 1997. IL-6 and APPs: Anti-inflammatory and immunosuppressive mediators. Immunology Today 18:428-432.
30. Toh CH, Dennis M. 2003. Disseminated intravascularcoagulation: Old disease, new hope. British Medical Journal 327: 974-977.
31. Weinberger A, Nyska A, Giler S. 1996. Treatment of experimental inflammatory synovitis with continuous magnetic field. Israel Journal of Medical Sciences 32:1197-1201.
32. Weiss DJ, Rashid J. 1998. The sepsis-coagulant axis: A review. Journal of Veterinary Internal Medicine 12:317-324.
33. World Health Organisation. 2006. Environmental health criteria 232 - Static fields. Geneva: WHO Press, World Health Organisation.